vs
NORTHERN TECHNOLOGIES INTERNATIONAL CORP（NTIC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是NORTHERN TECHNOLOGIES INTERNATIONAL CORP的1.5倍（$35.5M vs $23.3M），NORTHERN TECHNOLOGIES INTERNATIONAL CORP净利率更高（1.0% vs -304.2%，领先305.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 9.2%），NORTHERN TECHNOLOGIES INTERNATIONAL CORP自由现金流更多（$-479.7K vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 5.8%）
该企业为一家美国航天科技公司，专注于地理空间情报、地球观测、在轨卫星服务业务，同时提供卫星产品及相关配套服务。其由数字地球公司与MDA控股公司合并而成，于2017年10月5日正式完成合并组建。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NTIC vs RXRX — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.3M | $35.5M |
| 净利润 | $237.8K | $-108.1M |
| 毛利率 | 36.0% | 59.8% |
| 营业利润率 | 4.0% | -304.8% |
| 净利率 | 1.0% | -304.2% |
| 营收同比 | 9.2% | 681.7% |
| 净利润同比 | -57.6% | 39.6% |
| 每股收益（稀释后） | $0.03 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $23.3M | $35.5M | ||
| Q3 25 | $22.3M | $5.2M | ||
| Q2 25 | $21.5M | $19.2M | ||
| Q1 25 | $19.1M | $14.7M | ||
| Q4 24 | $21.3M | $4.5M | ||
| Q3 24 | $23.3M | $26.1M | ||
| Q2 24 | $20.7M | $14.4M | ||
| Q1 24 | $20.8M | $13.8M |
| Q4 25 | $237.8K | $-108.1M | ||
| Q3 25 | $-1.1M | $-162.3M | ||
| Q2 25 | $121.8K | $-171.9M | ||
| Q1 25 | $434.3K | $-202.5M | ||
| Q4 24 | $561.1K | $-178.9M | ||
| Q3 24 | $1.8M | $-95.8M | ||
| Q2 24 | $976.6K | $-97.5M | ||
| Q1 24 | $1.7M | $-91.4M |
| Q4 25 | 36.0% | 59.8% | ||
| Q3 25 | 37.9% | -183.8% | ||
| Q2 25 | 38.4% | -4.9% | ||
| Q1 25 | 35.6% | -48.0% | ||
| Q4 24 | 38.3% | -181.4% | ||
| Q3 24 | 43.8% | 53.7% | ||
| Q2 24 | 38.2% | 36.2% | ||
| Q1 24 | 40.0% | 19.1% |
| Q4 25 | 4.0% | -304.8% | ||
| Q3 25 | 4.2% | -3327.6% | ||
| Q2 25 | 4.0% | -916.8% | ||
| Q1 25 | -1.7% | -1297.9% | ||
| Q4 24 | 5.2% | -4042.4% | ||
| Q3 24 | 11.8% | -377.1% | ||
| Q2 24 | 7.4% | -697.4% | ||
| Q1 24 | 10.6% | -698.4% |
| Q4 25 | 1.0% | -304.2% | ||
| Q3 25 | -4.9% | -3135.3% | ||
| Q2 25 | 0.6% | -894.2% | ||
| Q1 25 | 2.3% | -1373.3% | ||
| Q4 24 | 2.6% | -3935.5% | ||
| Q3 24 | 7.9% | -367.5% | ||
| Q2 24 | 4.7% | -676.6% | ||
| Q1 24 | 8.2% | -662.4% |
| Q4 25 | $0.03 | $-0.17 | ||
| Q3 25 | $-0.11 | $-0.36 | ||
| Q2 25 | $0.01 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.50 | ||
| Q4 24 | $0.06 | $-0.56 | ||
| Q3 24 | $0.19 | $-0.34 | ||
| Q2 24 | $0.10 | $-0.40 | ||
| Q1 24 | $0.17 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $72.4M | $1.1B |
| 总资产 | $104.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $6.4M | $743.3M | ||
| Q3 25 | $7.3M | $659.8M | ||
| Q2 25 | $6.8M | $525.1M | ||
| Q1 25 | $5.1M | $500.5M | ||
| Q4 24 | $5.6M | $594.4M | ||
| Q3 24 | $5.0M | $427.6M | ||
| Q2 24 | $5.8M | $474.3M | ||
| Q1 24 | $4.8M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $72.4M | $1.1B | ||
| Q3 25 | $72.1M | $1.0B | ||
| Q2 25 | $72.4M | $919.1M | ||
| Q1 25 | $69.7M | $933.9M | ||
| Q4 24 | $70.2M | $1.0B | ||
| Q3 24 | $71.2M | $524.6M | ||
| Q2 24 | $68.9M | $584.4M | ||
| Q1 24 | $68.4M | $401.2M |
| Q4 25 | $104.0M | $1.5B | ||
| Q3 25 | $102.7M | $1.4B | ||
| Q2 25 | $99.3M | $1.3B | ||
| Q1 25 | $93.7M | $1.3B | ||
| Q4 24 | $94.0M | $1.4B | ||
| Q3 24 | $94.7M | $726.5M | ||
| Q2 24 | $89.3M | $775.9M | ||
| Q1 24 | $87.3M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $341.9K | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-479.7K | $-47.3M |
| 自由现金流率自由现金流/营收 | -2.1% | -133.1% |
| 资本支出强度资本支出/营收 | 3.5% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.44× | — |
| 过去12个月自由现金流最近4个季度 | $-1.8M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $341.9K | $-46.1M | ||
| Q3 25 | $-1.4M | $-117.4M | ||
| Q2 25 | $609.7K | $-76.4M | ||
| Q1 25 | $803.7K | $-132.0M | ||
| Q4 24 | $2.4M | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | $1.9M | $-82.2M | ||
| Q1 24 | — | $-102.3M |
| Q4 25 | $-479.7K | $-47.3M | ||
| Q3 25 | $-1.4M | $-117.6M | ||
| Q2 25 | $-171.2K | $-79.6M | ||
| Q1 25 | $293.1K | $-133.8M | ||
| Q4 24 | $1.2M | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | $869.4K | $-83.4M | ||
| Q1 24 | — | $-109.0M |
| Q4 25 | -2.1% | -133.1% | ||
| Q3 25 | -6.3% | -2272.5% | ||
| Q2 25 | -0.8% | -413.9% | ||
| Q1 25 | 1.5% | -907.4% | ||
| Q4 24 | 5.5% | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | 4.2% | -578.5% | ||
| Q1 24 | — | -789.9% |
| Q4 25 | 3.5% | 3.5% | ||
| Q3 25 | 0.2% | 4.7% | ||
| Q2 25 | 3.6% | 16.4% | ||
| Q1 25 | 2.7% | 12.4% | ||
| Q4 24 | 5.7% | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | 5.2% | 8.2% | ||
| Q1 24 | — | 48.2% |
| Q4 25 | 1.44× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.01× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.99× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
RXRX
暂无分部数据
